Gary Connett

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.3K citations · Full text

Mendelian Disorder, Genetics, Ivacaftor Combination Regimen +2

Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis

Robert P. Howlin, Katrina Cathie, Luanne Hall‐Stoodley et al. · Molecular Therapy · 2017 · 198 citations · Full text

Antimicrobial Susceptibility, Antibiotics, Low-dose Nitric Oxide +8

Use of 16S rRNA Gene Profiling by Terminal Restriction Fragment Length Polymorphism Analysis To Compare Bacterial Communities in Sputum and Mouthwash Samples from Patients with Cystic Fibrosis

Geraint B. Rogers, M. P. Carroll, David J. Serisier et al. · Journal of Clinical Microbiology · 2006 · 145 citations · Full text

Prevention of viral induced asthma attacks using inhaled budesonide.

Gary Connett, Warren Lenney · Archives of Disease in Childhood · 1993 · 142 citations · Full text

Asthma, Inhaled Budesonide, Lung Inflammation +10

Cystic Fibrosis Diagnosed After 2 Months of Age Leads to Worse Outcomes and Requires More Therapy

Erika Sims, Allan Clark, Jonathan McCormick et al. · PEDIATRICS · 2007 · 123 citations